Insighta develops early cancer detection tests and clinical trials, focusing on expanding screening to a wider range of cancer types. Their work aims to improve early diagnosis and treatment outcomes for various cancers.
Funding
$30M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer screening methods often detect the disease at later stages, reducing treatment effectiveness and survival rates. Existing screening options may also be invasive, costly, and not readily accessible to a large portion of the population, leading to delayed diagnoses.
Solution
Insighta is developing a liquid biopsy platform, FRAGMA, for multi-cancer early detection using a simple blood draw. The technology analyzes cell-free DNA fragmentation patterns and methylation aberrations, which are indicative of various cancers, without requiring bisulfite treatment or enzymatic conversion. By identifying cancers at earlier stages, Insighta aims to improve treatment outcomes and increase accessibility to cancer screening through a low-cost method. The FRAGMA technology leverages a convolutional neural network to analyze somatic alterations and methylation patterns in circulating DNA.
Target Audience
Insighta's primary target audience includes individuals aged 50 years or older, current or former smokers with a significant smoking history, and those undergoing lung cancer screening.
Features
- Proprietary cfDNA technology for non-invasive cancer detection
- FRAGMA technology analyzes DNA methylation status without bisulfite treatment or enzymatic conversion
- High accuracy in pre-clinical data, with AUC scores of 0.98 for liver cancer, 1.0 for colorectal cancer, and 0.90 for lung cancer
- Applicable for early detection of multiple cancer types
- Low-cost method, increasing accessibility of early cancer detection
- Clinical trials are being conducted to validate the technology's ability to accurately and reliably detect cancer